ArticleFrontiers in veterinary science2026
Case Report: Long term multimodality treatment of canine hepatocellular carcinoma with serial monitoring of serum alpha-fetoprotein.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 13-year-old spayed female Shih Tzu presented with a several-month history of progressively increasing liver enzyme activities concurrent with managed hyperadrenocorticism. Diagnostic imaging revealed a solitary hepatic mass originating from the caudate process of the caudate lobe adhering to the caudal vena cava. Hepatocellular carcinoma (HCC) was confirmed via histopathological examination of an ultrasound-guided tru-cut biopsy, accompanied by a markedly elevated serum alpha-fetoprotein (AFP) concentration. Molecular targeted therapy with olaparib was initiated since complete surgical resection was unachievable due to tumor adherence to the caudal vena cava and conventional chemotherapy has limited efficacy for canine HCC, based on genomic profiling. Following objective tumor progression and worsening mass effect after 2 months, cytoreductive surgery was performed. Postoperatively, olaparib and canine interleukin-15 (cIL-15) immunotherapy were instituted to control potential micrometastases. The patient achieved clinical and radiographic stability for a 10-month follow-up period, accompanied by a significant drop in serum AFP levels. However, following the discontinuation of cIL-15 and subsequent reduction of olaparib dosage because of suspected adverse effects, serum AFP levels rebounded progressively, and tumor recurrence was confirmed via ultrasonography. The patient died 20 months after the initial detection of the mass. This case describes the clinical course of canine HCC managed with a multimodal therapeutic approach and highlights the potential utility of serum AFP as an adjunctive biomarker for disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.